x

Posted 13 March, 2023

ObsEva SA appointed Will Brown as new CEO

Nasdaq:OBSV appointed new Chief Executive Officer Will Brown in a 8-K filed on 13 March, 2023.


  As previously announced, effective February 23, 2023, Will Brown, who has served as the Company's Chief Financial Officer since January 2022, was appointed as Interim Chief Executive Officer of the Company.  

Don't how to trade CEO change? Read Reasons for CEO Turnover and Effect on Stock Performance.
Overview of ObsEva SA
Health Care/Life Sciences • Biotechnology
ObsEva SA is a clinical-stage biopharmaceutical company, which engages in the research and development of therapeutic treatments for women's reproductive health and pregnancy. It offers biopharmaceutical drugs addressing conditions compromising pregnancy from conception to birth. The company was founded by Ernest Loumaye and André Chollet on November 14, 2012 and is headquartered in Geneva, Switzerland.
Market Cap
$11.0M
View Company Details
Relevant filing section
Item 5.02 
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. 


Director Resignation and Transition 

On March 10, 2023, Annette Clancy, chair of the Board of Directors (the "Board") of ObsEva SA (the "Company"), notified the Company of her intention to resign from the Board, effective immediately. Effective March 13, 2023, the Board appointed Ernest Loumaye, co-founder of the Company and member of the Board, to succeed Ms. Clancy and serve as interim chair of the Board until the Company's 2023 Annual General Meeting of Shareholders, at which time he is expected to be nominated for this position for the upcoming year. 

Chief Executive Officer Transition 

As previously announced, effective February 23, 2023, Will Brown, who has served as the Company's Chief Financial Officer since January 2022, was appointed as Interim Chief Executive Officer of the Company. On March 13, 2023, the Company announced that Fabien de Ladonchamps, will be appointed as Chief Executive Officer of the Company with an anticipated effective date of May 1, 2023. Mr. Brown will continue to serve as Interim Chief Executive Officer until the effectiveness of Mr. de Ladonchamps' appointment. The Company expects to enter into an employment agreement with Mr. de Ladonchamps setting forth the terms and conditions of his employment as Chief Executive Officer. 

Mr. de Ladonchamps, age 44, has served as the Company's Vice President, Corporate Affairs and Finance since March 1, 2023. He previously served as the Company's Chief Administrative Officer from January 2021 to November 2022, interim Chief Financial Officer from April 2020 to December 2020, Vice President Corporate Affairs and Finance from January 2019 to April 2020, Vice President of Finance from January 2016 to December 2018 and Finance Director from October 2013 to December 2015. Mr. de Ladonchamps is a biotech executive with 25 years of experience in finance and administrative roles, primarily with Swiss biotech companies. He served as the sole finance and accounting officer for the Company for a total of four years during which over $110 million in equity proceeds were raised through private and public financings. Mr. de Ladonchamps was instrumental in the Company's listings on both The Nasdaq Stock Market in 2017 and the Swiss Exchange in 2018. Prior to joining the Company, Mr. de Ladonchamps held a variety of management roles at Addex Therapeutics from 2008 to 2013. Mr. de Ladonchamps holds a degree in Finance and Accounting from the Lyon III University in Lyon, France.